Trial
NCT03068468
Study of BIIB092 in Participants With Progressive Supranuclear Palsy
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Biogen
Collaborators
—
Condition
Supranuclear Palsy, Progressive
Intervention
BIIB092
Why stopped
251PP301(PASSPORT) primary endpoint was not met;Biogen decision to close the study early. There were no safety concerns with the PASSPORT study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-12-21